Boehringer Ingelheim taps Philogen DNA-encoded chemistry tech

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Antiv3D)
(Image: iStock/Antiv3D)

Related tags: Molecule

Boehringer Ingelheim and Philogen have signed a multi-target research agreement to discover and optimize new small molecule therapeutics for unmet medical needs.

The collaboration leverages Philogen’s DNA-Encoded Chemistry technology and Encoded Self-Assembling Chemical (ESAC) platform.

According to the Swiss-Italian company, the complementary discovery technologies enable the screening of up to billions of small molecules. The technology also optimizes hit compounds in a “fully automatic, DNA-tagged, fragment-based drug discovery manner​.”

Philogen DNA-Encoded libraries are extremely pure and based on smart design in order to provide a rich diversity without the need to work with huge and poorly manageable libraries. Moreover, ESAC technology allows a very fast and efficient way to optimize initial hit compounds and perform lead expansion,​” a Philogen representative told Outsourcing-Pharma.com.

Philogen is delighted to have expanded its ongoing collaborations with Boehringer Ingelheim beyond the area of biologics​,” they added.

The companies have previously worked together as part of a collaboration to explore investigate treatment approaches for Acute Myeloid Leukemia (AML).

Financial details of the agreement were not released.

Related news

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Related suppliers

Follow us

Products

View more

Webinars